<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Although there are several reports on the antibacterial activity of EOs against 
 <italic class="italic">S. aureus</italic> (e.g., see [
 <xref rid="B59-molecules-23-01679" ref-type="bibr" class="xref">59</xref>,
 <xref rid="B60-molecules-23-01679" ref-type="bibr" class="xref">60</xref>,
 <xref rid="B61-molecules-23-01679" ref-type="bibr" class="xref">61</xref>]), many of these studies involved high EO concentrations and only a few studies evaluated the effects of EOs at concentrations below 50 μg/mL. For example, Yamani et al. reported that EOs from 
 <italic class="italic">Ocimum tenuiflorum</italic> at 2.25–2.5 μg/mL had bacteriostatic activity against two 
 <italic class="italic">S. aureus</italic> strains, including MRSA [
 <xref rid="B62-molecules-23-01679" ref-type="bibr" class="xref">62</xref>]. The main volatile constituents of 
 <italic class="italic">O. tenuiflorum</italic> EOs are monoterpenes and sesquiterpenes [
 <xref rid="B62-molecules-23-01679" ref-type="bibr" class="xref">62</xref>]. Likewise, EOs of 
 <italic class="italic">Aloysia polystachya</italic> at 3.64, 7.28, and 29.13 μg/mL inhibited 
 <italic class="italic">S. aureus</italic> ATCC 25923, 
 <italic class="italic">S. aureus</italic> ATCC 29213, and MRSA, respectively [
 <xref rid="B63-molecules-23-01679" ref-type="bibr" class="xref">63</xref>]. The main compounds in 
 <italic class="italic">A. polystachya</italic> EOs are carvone (78.9%) and limonene (14.2%) [
 <xref rid="B63-molecules-23-01679" ref-type="bibr" class="xref">63</xref>]. Here we found that EOs from 
 <italic class="italic">F. ovina</italic> exhibited antibacterial activity against MRSA, with FOEO
 <sub class="sub">Rfl</sub>, FOEO
 <sub class="sub">Rfr</sub>, and FOEO
 <sub class="sub">Sfr</sub> at concentrations of 19–22 μg/mL (
 <xref rid="molecules-23-01679-t002" ref-type="table" class="xref">Table 2</xref>). Thus, this is the first study showing effective antibacterial activity of EOs from 
 <italic class="italic">F. ovina</italic> against a clinically-relevant MRSA strain (USA300).
</p>
